SynCo Bio Partners B.V. has signed an agreement to produce Syntaxin’s novel drug candidate SXN101959. Syntaxin is developing SXN101959 for the therapeutic treatment of acromegaly as a primary indication. SynCo will assist Syntaxin in scale-up and manufacture of multiple batches of bulk drug substance and drug product of SXN101959 for non-clinical, Phase I and Phase II clinical trials. In acromegaly, hypersecretion of growth hormone usually occurs from a benign pituitary tumour. Current ...